CannaBioLabs

Compassionate Cannabis Biotechnology

Our Mission
Engineering Compassionate Medicine with Synthetic Biology

CannaBio Labs genetically engineers commercially useful traits into

cannabis plants.
Our first proposed product is a GMO medicinal cannabis strain with THC
levels >50%
We are team of molecular biologists and entrepreneurs with a proven track
record in plant molecular genetics.
Market Opportunity

Cannabis industry is
worth ~17bn USD
Projected to reach ~44bn
USD by 2020
Medical cannabis market
worth ~2.7bn USD in CA
alone*.

*Ackrell Capital. (n.d.). U.S.

Cannabis Investment Report
2016. Retrieved from
https://www.ackrell.com/canna
bis/
Market Opportunity
Our Unique Intellectual Property Position
A proprietary cannabis genetic engineering toolkit

Plug-and-Play Expression System for Many Genes

 Our Product
A Commercially superior, genetically engineered (GE) strain that produces higher levels of THC than what is
possible through traditional plant breeding.

Desirable gene of
interest expressed in
cannabis which
increases THC content
Current Problems With Extractions
Patients overpaying for legal medicinal THC and CBD oils to treat epilepsy,
multiple sclerosis, and cancer chemotherapy symptoms.
Cannabis growers are only achieving 10% efficiency in extraction.
Why Growers will use our product
THC Extraction Costings and Profit (Generic Strain)

Amount of plant Extraction Cost 10% Oil Market Value Final Product Revenue Cost of Net profit
product (kg) (olive oil Yield (kg) of Oil before other growing
extraction) $/kg) (USD/kg) non-growing/extraction ($/kg)
expenses

1 $39.70 0.1 $40000 $4000 $1248.80 $2751.20

THC Extraction Costings and Profit (CannaBio Strain)

Amount of plant Extraction Cost 50% Oil Market Value Final Product Revenue Cost of Net profit
product (kg) (olive oil Yield (kg) of Oil before other growing
extraction) $/kg) (USD/kg) non-growing/extraction ($/kg)
expenses

1 $39.70 0.5 $40000 $20000 $1248.80 $18751.20

Assumptions: Model only considers extraction and growing cost, not distribution.
Oil yield is dependent only on plant composition
How we do it: High THC GMO Strains

An example of cannabis plant genetic engineering

Where is Cannabis Biotechnology Today?
Publication Journal Year High-Level Summary Significance
Tissue culture and In Vitro Cell 2003 A marker gene was successfully Genetic engineering
Agrobacterium-mediated Dev Biol -Plant introduced and confirmed, but a full technology works, but
transformation of hemp transgenic plant could not be regenerating plants is
(Cannabis sativa L.) regenerated. hard. Very low
transformation efficiency
(~1%).

Hemp (Cannabis sativa Agrobacterium 2014 A marker gene was successfully Transformation efficiency
L.) Protocols, introduced and confirmed, but a full was dramatically
Volume 2 transgenic plant could not be increased (~31%)
regenerated.

In vitro mass propagation Journal of 2016 Development of an improved and Regeneration efficiency
of Cannabis sativa L.: A Applied highly efficient micropropogation improved dramatically
protocol refinement using Research on protocol to regenerate full plants. (100% survival rate).
novel aromatic cytokinin Medicinal and
meta-topolin and the Aromatic Plants
assessment of
eco-physiological,
biochemical and genetic
fidelity of
micropropagated plants

Routine genetic transformation of cannabis is now feasible

 Competitors
Biopharmaceuticals/Extracts
Synthetic Cannabinoids Cannabinoid Extracts

Cannabis Biotechnology and Genomics

How are we unique?
We are a true plant synthetic biology startup building the genetic engineering platform which larger
companies can license or acquire.

CannaBio Labs has patents pending on its proprietary genetic engineering tools for cannabis and its
unique approach to overexpressing cannabinoids and therapeutics.
Proof of Concept: GMO Fluorescent Cannabis

Link: https://vimeo.com/132267796
Project Timeline
Route to Market

(US) License License to large-scale medicinal

Intellectual Property cannabis growers
(proprietary strains)

Contract
manufacturing in EU

CannaBio
through licensed
partners under strict
cGMP compliance

Labs THC/CBD extracts to medical cannabis

dispensaries
Ask
Fundraising:
100,000 USD in exchange for 5% equity
(2m USD pre-money valuation)

Funding will prove out its core, patent-pending technology in 15 months or less.
The company is projected to begin generating revenue within two years or less.

Logistics:
Head Office secured in Cork, Ireland.
Need to secure a lab space with a tissue culture room and a company office in CA

Company Structure:
Need to be as tax-efficient as possible while working within existing laws and
regulations
Potential Sources of Seed Capital
Private Venture Capital
The Team

Antonio Lamb Dr. Kwang-Chul Kwon

Chief Executive Officer Chief Scientific Officer
CoFounder CoFounder

Expertise: Expertise:

Plant Molecular Genetics 15 years of experience

Business Development Proven track record in
B.Sc. Molecular Biology plant genetic engineering
Ph.D., Plant Biology
CannaBio Labs
Compassionate Cannabis Biotechnology

Contact:

info@cannabiolabs.co
 Appendix
Highest recorded % THC content in marijuana is ~37.2%*

*Mehmedic,Z., Chandra,S., Slade,D., Denham,H., Foster,S., Patel,A.S., Ross,S.A., Khan,I.A. and ElSohly,M.A. (2010) Potency
Trends of 9-THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008. Journal of Forensic
Sciences, 55, 12091217.
Operational/Commercial Strategy
Use California subsidiary company to conduct strain development R&D
Set up Tech Transfer/IP holding company in Ireland
Cannabis IP kept in Ireland
Begin licensing to US and EU firms
Begin contract manufacturing for patients in Ireland/EU (Help Not Harm)
Licensing in US with legal growers/medical dispensaries.
Pros: Irish government policies favor foreign direct investment,
low corporation tax (12.5% vs. 35% in America)
Ireland now recognizes medicinal cannabis as a legitimate medicine for several critical diseases
6.25% Tax on all IP revenue through Irish knowledge development box scheme

Tech/IP transfer Licensing Revenue

R&D Facilities HQ and

IP Holding
 The Team

Antonio Lamb Dr. Kwang-Chul Kwon

Chief Executive Officer Chief Scientific Officer
CoFounder CoFounder

Expertise: Expertise:

Plant Molecular Genetics 15 years of experience

Business Development Proven track record in
B.Sc. Molecular Biology plant genetic engineering
Ph.D., Plant Biology